[Proper use of carbapenem antibiotics based on the feature in the treatment of infectious diseases (discussion)]].
Kaku
Mitsuo
M
Inoue
Matsuhisa
M
Sagawa
Keisuke
K
Nasu
Masaru
M
Yokoyama
Takashi
T
D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy; D015780:Carbapenems / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D015377:Cilastatin / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000077728:Cilastatin, Imipenem Drug Combination; D004334:Drug Administration Schedule; D004338:Drug Combinations; D024881:Drug Resistance, Bacterial; D006801:Humans; D015378:Imipenem / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000077731:Meropenem; D013845:Thienamycins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D017211:Treatment Failure; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D015780:Carbapenems; D004338:Drug Combinations; D013845:Thienamycins; D015091:beta-Alanine; C075316:panipenem-betamipron; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination; D000077731:Meropenem; C065257:biapenem